Inactive Instrument

Analyst Reco. Mylan N.V. Nasdaq

Equities

MYL

NL0011031208

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

Atomo Diagnostics Wins AU$570,000 HIV Self-Tests Order	Apr. 14	MT
Stonex Group Insider Sold Shares Worth $488,142, According to a Recent SEC Filing	Mar. 25	MT
India's Nifty 50 set to open at new record high, buoyed by strong growth data	Nov. 30	RE
Piper Sandler Adjusts Viatris' Price Target to $11 From $10, Maintains Neutral Rating	Nov. 22	MT
Another clue on monetary policy?	Nov. 08
BofA Securities Downgrades Viatris to Underperform From Neutral, Adjusts Price Target to $9 From $13	23-10-23	MT
UBS Adjusts Viatris Price Target to $11 From $12, Maintains Neutral Rating	23-10-20	MT
Out with the old	23-10-02
Inflation, Interest-Rate Prospects Lift Wall Street Pre-Bell; Asia, Europe Off	23-08-07	MT
Barclays Downgrades Viatris to Underweight From Equalweight, Price Target is $11	23-06-23	MT
Fitch Affirms IDR of Viatris at 'BBB'; Outlook Stable	23-04-26	AQ
Barclays Downgrades Viatris to Equal Weight From Overweight, $11 Price Target	23-04-24	MT
Barclays Adjusts Price Target on Viatris to $16 From $15, Keeps Overweight Rating	23-02-28	MT
BMO Capital Downgrades Viatris to Market Perform From Outperform, Adjusts Price Target to $14 From $16	23-02-17	MT
Barclays Adjusts Price Target on Viatris to $15 From $16, Maintains Overweight Rating	23-02-01	MT
Jefferies Upgrades Viatris to Buy From Hold, Adjusts Price Target to $15 From $13	23-01-27	MT
Indian shares set for muted open ahead of GDP data	22-11-29	RE
UBS Upgrades Viatris to Neutral From Sell, Adjusts Price Target to $12 From $9	22-11-10	MT
Piper Sandler Upgrades Viatris to Neutral From Underweight, Price Target is $10	22-11-08	MT
Barclays Adjusts Viatris' Price Target to $16 From $21, Reiterates Overweight Rating	22-10-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mylan N.V. Nasdaq

Equities

MYL

NL0011031208

Analyst Reco.

Filters